Research programme: epimorphin-derived peptide - Sumitomo Electric

Drug Profile

Research programme: epimorphin-derived peptide - Sumitomo Electric

Alternative Names: Epimorphin-derived peptide - Sumitomo Electric; Epimorphin-derived peptide research programme - Sumitomo Electric; EPM; pep 7

Latest Information Update: 31 Aug 2005

Price : $50

At a glance

  • Originator Sumitomo Electric Industries
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Alopecia

Most Recent Events

  • 31 Aug 2005 A preclinical study has been added to the pharmacokinetics and Skin Disorders pharmacodynamics sections
  • 31 Aug 2005 This programme is still in active development for Alopecia
  • 07 Mar 2002 Preclinical trials in Alopecia in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top